Allergan plc (AGN)

As expected, Allergan reported solid results that modestly beat consensus estimates.    I am trying to add in premarket trading in order to bring this position to large in size.   Sales rose by about $100 million more than expected and the bottom li...

Retail and biotech just continue to be horrific performers -- across the board. And, given their vulnerability to year-end tax-loss selling, I don't see a respite over the next two months. I remain long only Dillard's (retail) and Allergan (biotech)...

"Pachalafaka, pachalafaka they whisper it all over Turkey pachalafaka, pachalafaka it sounds so romantic and perky oh I know that phrase will make me thrill always for it reminds me of you, my sweet just the mention of that tender word of love gives...

Here are my trades to this point today. I added to my Allergan long.   I initiated a General Motors short and added to my Amazon short.

For a change, some good drug approval news (out of China) for Allergan this morning.    I am medium in size in this name.

I have lowered today's Allergan buy average to $177.35 and I have added to my Hartford Financial Group long.  

My average price on today's Allergan buy is $177.87.

This morning I added to Allergan on weakness in biotech -- a true contrarian and counterintuitive bet considering the struggles of Celgene et al. However, I am still only medium in size in my AGN position.

My average buy on Allergan was $178.85 today. Still medium sized.

The dip of death for Allergan , as the shares traded down to $179 this morning, may have been a successful test.   I added into the decline.

This afternoon I have moved from small sized to medium sized in Allergan at $183.50. * The last tranche of sales I made of AGN was almost $30 higher than the current price. Since then the company has been legally challenged in an important product o...

With thirty minutes to go: * Watching CNBC and the rest of the business media, one would conclude that "everyone is in the pool." It is, as one talking head just declared..."a buy/buy scenario." (Enough said/written). * The bond market's decline was...

Allergan is now about $30 below my recent sale only a few weeks ago.   I have not yet added back to this name.

Barron's discusses the $1.5 billion hole in Allergan .   My thoughts remain the same -- among other things, upside to estimates no longer exists and my AGN position remains small. Nevertheless, AGN's valuation is quite reasonable and I would be a bu...

"Everyone is putting money in the market, so you might as well follow."  -- CNBC talking head  In the aggregate, the markets were uneventful -- with another remarkably narrow range in the S&P Index.  But there were some major movers.  On the upside,...

"We are disappointed by the Federal District Court's decision on the Restasis patents. We are carefully reviewing the decision and are considering all options. Allergan remains committed to vigorously defending the intellectual property of our produ...

Allergan has continued to decline today on a just received and adverse court decision on Restasis patents.   Here are my recent thoughts on the name.     

"Drug companies are getting away with murder." - PresidentTrump   And these words, corralling fears of drug price controls, are taking down Allergan , Teva (which I would sell), big pharma shares and other drug company share prices now.   My sole in...

"While options can give market participants the protection they are intended to provide, they can also increase the degree of a counter move, once it gets going, as those who wrote the protection scramble to unwind their own exposure." -- Kass Diary...